Health
STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more
TL;DR
- Novartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deaths
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Nov 9, 2026 · Updated 11/9/2026, 2:33:28 PM · Reported with: STAT
Sources (1)
NRI Bytes writes its own articles from the reporting below.
STAT — STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and moreUp next · Health
STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke
Read next →
More stories
Health
Pedestrian struck by vehicle in Mississauga
1h ago
Health
US citizen shot by ICE officer near children’s bus stop sues government for $25m
2h ago
Health
Glycerin vs. hyaluronic acid: Which ingredient is best for winter?
2h ago
Health
Witness testifies about mental health of author Steven Galloway's accuser
3h ago
